[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484-254-6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 66, "title": "Co-Founder, Chief Scientist Officer & Chairman", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": 873696, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen H. Willard Esq.", "age": 62, "title": "Acting Corporate Secretary, CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 501186, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 61, "title": "Chief Technology Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Seth L. Van Voorhees Ph.D.", "age": 62, "title": "Treasurer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 399960, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard Clavano Narido", "age": 45, "title": "Interim CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1978, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 76, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dennis K. McBride Ph.D.", "title": "Chief Strategy Officer & Senior Scientist", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 60, "title": "Chief Business Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.485, "open": 0.49, "dayLow": 0.47, "dayHigh": 0.5269, "regularMarketPreviousClose": 0.485, "regularMarketOpen": 0.49, "regularMarketDayLow": 0.47, "regularMarketDayHigh": 0.5269, "beta": 0.988, "forwardPE": -1.9426924, "volume": 1033480, "regularMarketVolume": 1033480, "averageVolume": 1456638, "averageVolume10days": 1977460, "averageDailyVolume10Day": 1977460, "bid": 0.46, "ask": 0.7, "bidSize": 100, "askSize": 200, "marketCap": 46684172, "fiftyTwoWeekLow": 0.221, "fiftyTwoWeekHigh": 1.2, "fiftyDayAverage": 0.4556, "twoHundredDayAverage": 0.382385, "currency": "USD", "enterpriseValue": 43221032, "floatShares": 57546893, "sharesOutstanding": 92425600, "sharesShort": 2714361, "sharesShortPriorMonth": 2874157, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0296, "heldPercentInsiders": 0.31108, "heldPercentInstitutions": 0.04494, "shortRatio": 2.39, "shortPercentOfFloat": 0.0427, "impliedSharesOutstanding": 92425600, "bookValue": -0.075, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -36059000, "trailingEps": -0.5, "forwardEps": -0.26, "enterpriseToEbitda": -1.307, "52WeekChange": -0.3082192, "SandP52WeekChange": 0.31995547, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NRXP", "underlyingSymbol": "NRXP", "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1512397800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e9e53629-f0c1-3f0f-8011-e7d950c4534d", "messageBoardId": "finmb_319388181", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.5051, "targetHighPrice": 5.5, "targetLowPrice": 2.0, "targetMeanPrice": 3.17, "targetMedianPrice": 2.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 8902000, "totalCashPerShare": 0.107, "ebitda": -33064000, "totalDebt": 10069000, "quickRatio": 0.461, "currentRatio": 0.677, "returnOnAssets": -1.08969, "returnOnEquity": -6.82612, "freeCashflow": -14752250, "operatingCashflow": -26783000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]